China Otsuka Pharmaceutical Co., Ltd.

China Otsuka Pharmaceutical Co., Ltd., the first Sino-Japanese joint venture and the first joint venture pharmaceutical companies in China, was co-invested by China Pharmaceutical Group, Tianjin Pharmaceutical Group Co., Ltd. and Japan's Otsuka Group in 1981.

The trademark "COP" was rated as China's well-known trademark, and nowadays, COP has become the integrated pharmaceutical manufacturer owning various products such as infusion, plastic ampoule injection, eye drops and nutrition infusion with its own brand. Currently, it has owned offices in 23 provinces and cities, and its marketing networks have covered 31 provinces and cities nationwide. COP has two affiliated companies — Guangdong Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. Dalian. In 2013, the consolidated revenue of COP was 860,000,000 yuan.

Japanese foreign shareholders: Japanese Otsuka Pharmaceutical Co., Ltd.

Otsuka Group was founded in 1921 and produced inorganic compounds initially. Nowadays, Otsuka Group has developed into a multinational enterprise group owning more than 140 companies. Otsuka Holdings Co., Ltd. was established in 2008 and became the listed company in Japan in 2010.

Otsuka Pharmaceutical Co., Ltd., one of the core companies of Otsuka Group, was founded in 1964. Its core businesses include pharmaceutical business and nutraceutical business. Pharmaceutical business focuses on central nervous system, cardio cerebral vascular system, digestive system, respiratory system, dermatology and ophthalmology and engages in development, production and sale of medical drugs. Because of its advanced technology, Otsuka Pharmaceutical infusion products are well known to world and have a market share of about 50% in Japan.